Africa’s First CoC Registry Goes Live for SA’s 20 September Trade Deadline 
Santamarina + Steta Strengthens Its Tax Practice with the Addition of Luis Curiel Pina and Francisco Carbajal Dominguez 
Berry AI and Culver’s Announce Brand-Wide Vision AI Deployment Across 1,000+ Restaurants 
Sensiba Names Monic Ramirez as Managing Partner Amid Firm-Wide Transformation LifeSci Acquisition II Corp. Announces Confidential Submission of S-4 Registration Statement Related to Proposed Business Combination
NEW YORK, June 16, 2021 (GLOBE NEWSWIRE) — LifeSci Acquisition II Corp. (NASDAQ: LSAQ), a…
Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present on Advances Using Camelina Platform to Produce PHA Bioplastic at 2021 Synthetic Biology: Engineering, Evolution and Design Virtual Conference
WOBURN, Mass., June 16, 2021 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience…
Mustang Bio to Present at the Raymond James Human Health Innovation Conference
WORCESTER, Mass., June 16, 2021 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a…
Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel
SAN DIEGO, June 16, 2021 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical…
Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions
Company announcement – No. 39/2021 Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at…
KBP Biosciences Announces A Greater Than 10 mm Hg Systolic Blood Pressure Reduction in The BLOCK-CKD Phase 2b Study of KBP-5074 in Advanced Chronic Kidney Disease Patients with Uncontrolled Hypertension as Published in Hypertension
KBP-5074, a highly-selective non-steroidal mineralocorticoid receptor antagonist, lowered clinic systolic blood pressure (SBP) by 10.2…
VistaGen Therapeutics Set to Join the Russell 2000® Index
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) — VistaGen Therapeutics, Inc. (NASDAQ: VTGN),…
Pamrevlumab Included in Pancreatic Cancer Action Network’s Adaptive Clinical Trial Platform
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) — FibroGen, Inc. (NASDAQ: FGEN) announced activation of…
Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI)
Supporting data in preclinical model of drug-resistant epilepsy demonstrate seizure-freedom in 70% of the NRTX-1001…
Selecta Biosciences to Participate at the Raymond James Human Health Innovation Conference
WATERTOWN, Mass., June 16, 2021 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology…
Jounce Therapeutics to Host Virtual R&D Day on June 23, 2021
CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage…
PharmaTher To Present At The H.C. Wainwright Psychedelics In Psychiatry And Beyond Virtual Conference
TORONTO, June 16, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB:…
Apexigen and the Nordic Society of Gynaecological Oncology – Clinical Trial Unit Announce Collaborative Phase 2 Study of Sotigalimab (APX005M) in Combination Therapy for Ovarian Cancer
-Study to be conducted at multiple sites across Europe through European Network of Gynaecological Oncological Trial…
Enlivex Annouces Participation in A.G.P.’s Upcoming 2021 Virtual Summer Healthcare Symposium
Nes Ziona, Israel, June 16, 2021 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the…
Impel NeuroPharma to Present at the Raymond James Human Health Innovation Conference
SEATTLE, June 16, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, a late-stage biopharmaceutical company focused on…
BeyondSpring Announces First Quarter 2021 Financial Results and Provides a Corporate Update
– NDA Filed by U.S. Food and Drug Administration (FDA) and given Priority Review for…
89bio to Participate in Upcoming Investor Conferences
SAN FRANCISCO, June 16, 2021 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical…
Motus GI Announces First Patients Enrolled in the European Union Feasibility Study of the Pure-Vu® System as a New Method for Bowel Cleansing in Patients With a History of Poor Bowel Preparation
FORT LAUDERDALE, Fla., June 16, 2021 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS)…
Aprea Therapeutics Announces Phase 1/2 Trial of Eprenetapopt + Venetoclax + Azacitidine in TP53 Mutant AML Meets Complete Remission Primary Efficacy Endpoint
37% CR rate in 30 efficacy-evaluable patients BOSTON, June 16, 2021 (GLOBE NEWSWIRE) — Aprea…
Adagene Announces Inclusion in FTSE Russell Indexes
SAN FRANCISCO and SUZHOU, China, June 16, 2021 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq:…